IntriCon

The Body-Worn Device Company

Safe Harbor Statement

Forward-looking statements contained in this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “continue” or other similar expressions. There are certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein. Reference is made to the company’s Annual Report on Form 10-K for the year ended December 31, 2008 for further information on such risk factors.

Company Information

- NASDAQ: “IIN”; Founded in 1977
- 580 employees
- Proprietary firmware that enhances performance of body-worn devices
- Expertise in ultra-miniature mechanics & electronics
- Acquired Datrix in August 2009 to enter the biotelemetry market
- Growing international presence
- $55+ million revenue, $17+ million market cap
- Two business segments: Body-Worn Device & Electronics (non-core)

IntriCon
The Body-Worn Device Company

Our Mission

IntriCon's mission is to enhance the mobility & effectiveness of **body-worn devices** that connect people to people & to the devices around them.

IntriCon
The Body-Worn Device Company

Body-Worn Devices



Revenue Breakdown



IntriCon
The Body-Worn Device Company

Profit Drivers

- Premium pricing power through application of digital firmware (e.g., “Intel Inside”) & wireless technology to established core business
- Improving margins by actively increasing percentage of proprietary content
- Actively pursuing appropriate M&A opportunities to build leadership position in body-worn devices, such as the Datrix cardiac diagnostic monitoring devices
- Maximizing R&D spending to increase revenue and margins in core business
- Market share expansion – higher volume
- Biotelemetry focus

Proprietary Technology
Ultra-Low Power Digital Signal Processing

Proprietary technology (firmware) means high-value, body-wearable features

- **Hearing & professional audio & security**
  - Adaptive feedback canceling
  - Directional microphone arrays
  - Active noise canceling
  - Voice feature extraction
  - Noise reduction

- **Medical biotelemetry**

Proprietary Technology
Ultra-Low Power Wireless

Performance comparison to Bluetooth:

- Allows miniaturization
- 25 times lower power consumption
- Lower power supply voltage

Ultra-low power wireless is superior in critical applications:

- Medical biotelemetry
- Hearing
- Professional audio
- Security

IntriCon
The Body-Worn Device Company

Company Evolution

Acquired Datrix – 2009

AME and DH Strategic Alliances – 2008

Acquired Tibbetts - 2007

Rebranded as IntriCon (IIN) - 2005

Sale of Non-Strategic Assets - 2001-2005

Purchased Lectret (Singapore) - 2001

Gorder Appointed CEO - 2001

RTI Sold to Selas - 1993

Gorder Founded RTI – 1977



Experienced Management Team

Mark Gorder	President, CEO & Founder
Scott Longval	CFO, Secretary & Treasurer
Chris Conger	VP of Research & Development
Mike Geraci	VP of Sales & Marketing
Dennis Gonsior	VP of Global Operations
Greg Gruenhagen	VP of Quality & Regulatory Affairs

. . . combined 120 years with IntriCon

Experienced Corporate Governance

Michael J. McKenna	**Chairman of the Board** Retired Vice Chairman, President & Director, Crown Cork & Seal Company, Inc.
Nicholas A. Giordano	**Chairman of the Audit Committee** Business Consultant Former President & CEO, Philadelphia Stock Exchange
Robert N. Masucci	**Director** Chairman, Barclay Brand Ferndon, Inc. Chairman, Montgomery Capital Advisors
Philip N. Seamon	**Director** President, Philip N. Seamon, Inc. Former Senior Managing Director, Corporate Finance, FTI Consulting, Inc. Former Partner, Price Waterhouse Coopers

IntriCon
The Body-Worn Device Company

International Presence

- **Arden Hills, MN (HQ)**
- Vadnais Heights, MN
- Singapore
- Camden, ME
- San Diego, CA
- Munich, Germany
- Anaheim, CA

Established Presence & Low-cost Manufacturing

IntriCon
The Body-Worn Device Company

Growth Drivers: Body-Worn Devices

- Over 65 age group fastest-growing segment in U.S., Europe & Japan
- Telemedicine using wireless miniature biosensors
- Increased spending on security, intelligence & defense
- Wireless becoming connectivity standard
- Demand for quality

Revenues



- 2009 Q3 YTD revenue was $41.5M, down 17% over prior-year period, primarily due to economy
- Medical revenue is up 11%, offset by 27% and 32% decrease in Hearing Health and Professional Audio Communications respectively
- Revenue has increased sequentially in each quarter of 2009
- Three year CAGR of 7.1%

Investment in R&D



- Increased investment in R&D 57% over past three years
- 2009 Q3 YTD investment in R&D was $2.5 million, or 5.9% of revenue
- In addition, we received a significant amount of customer-funded R&D
- Have access to AME and Dynamic Hearing engineers to assist in developing ULP wireless and DSP technologies

IntriCon
The Body-Worn Device Company

Net Income



- 2009 Q3 YTD net loss of $2.3M
- Body-Worn Device segment loss of $1.4M, non-core Electronics segment loss of $0.4M and non-recurring costs associated with Datrix transactions of $0.5M
- Decrease driven by challenging economic environment, loss of a one-time HH program, decline in non-core Electronics segment and higher stock option expense

IntriCon
The Body-Worn Device Company

2009 Proforma Net Income

	Q109	Q209	Q309	YTD
GAAP basis net loss	$ (989)	$ (598)	$ (736)	$(2,323)
Non-recurring acquisition costs	--	14	263	277
Non-recurring debt financing costs	--	--	269	269
Depreciation and amortization	616	629	590	1,835
Stock-based compensation	137	135	146	418
Proforma net income (loss)	**$ (236)**	**$ 180**	**$ 532**	**$ 476**

- Generated progressively improved results for each of the three quarters of 2009 despite the difficulties posed by the current economic climate.

IntriCon
The Body-Worn Device Company

Balance Sheet

(in thousands)

	2009Q3	2008	2007
Cash	$ 1,282	$ 249	$ 381
Working capital	$ 9,890	$10,602	$ 9,365
Total funded debt	$ 8,831	$ 7,692	$ 8,440
Shareholders' equity	$18,964	$20,312	$18,597

- Cash cycle days of 72, using a three month rolling average
- $8.8M of funded debt - $5.0M domestic revolver, $0.4M international revolver, $3.4M long-term note
- $3.0M of availability under existing domestic revolver

IntriCon
The Body-Worn Device Company

Cash Flow

(in thousands)

	2009Q3	2008	2007
Net cash provided by operating activities	$ 1,420	$ 2,452	$ 3,533
Net cash used by investing activities	$ (2,001)	$ (98)	$(7,060)
Net cash provided (used) by financial activities	$ 1,610	$ (2,480)	$ 3,740
Effect of exchange rate changes on cash	$ 4	$ (6)	$ 8
Net increase (decrease) in cash	$ 1,033	$ (132)	$ 221

- Secured new $11.5M credit facility in August 2009, consisting of $8.0 revolver and $3.5M term note
- Generated $1.4M of positive operating cash flow, driven by tight working capital management

IntriCon
The Body-Worn Device Company

Corporate Strategies

- IIN is conservatively managing the business by reducing expenses & focusing on remaining cash flow positive, while prudently investing in strategic R&D
- Goal is to improve gross margins from current levels to 30% by 2012
- Over next five years IIN intends to make multiple strategic acquisitions that enhance our position as the body-worn medical device company
- Increase percentage of proprietary IIN content in all devices
- Pursue strategic partnerships to develop new technologies

Why IntriCon?

- Leader in high-performance body-worn devices
- Increasing market opportunity for body-worn devices
- Proprietary technology is well positioned for future market opportunities when economy rebounds
- Real markets - Realistic goals

IntriCon

The Body-Worn Device Company

Questions & Answers